Apurv Khanna, MD
Nephrology · Duluth, MNNPI 1497744916
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.2% of the total across 139 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Amgen at 27.5% of the total. Reporting peaked in 2021 at $1,236 and has fallen 98.1% since, to $23 in 2025.
Across 139 payments — averaging $23.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$884
- AstraZeneca$524
- Aurinia Pharma U.S., Inc.$314
- GSK$238
- Bayer$222
- Daiichi Sankyo Inc.$200
- plus $828 from 14 others
What the payments were for
- Consulting fees$802%
- Speaking & faculty fees$391%
- Food & beverage$3,08696%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 31 | $884 |
| AstraZeneca(2 entities) | 22 | $524 |
| Aurinia Pharma U.S., Inc. | 9 | $314 |
| GSK | 10 | $238 |
| Bayer | 11 | $222 |
| Daiichi Sankyo Inc. | 10 | $200 |
| Fresenius USA Marketing, Inc. | 13 | $190 |
| Akebia Therapeutics Inc | 9 | $158 |
| Vifor Pharma, Inc. | 7 | $117 |
| Otsuka America Pharmaceutical, Inc. | 4 | $69 |
| Mallinckrodt Enterprises LLC | 3 | $66 |
| Alnylam Pharmaceuticals Inc. | 2 | $41 |
| BD | 1 | $39 |
| Nxstage Medical, Inc. | 1 | $28 |
| Bard Peripheral Vascular, Inc. | 1 | $26 |
| OPKO Pharmaceuticals, LLC | 1 | $25 |
| Novartis | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,209 in reported general payments places this provider in the 85th percentile of 208 nephrology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 15 | $42,997 |
| JardianceEmpagliflozin | 11 | $6,093 |
| Sevelamer Carbonate | 31 | $3,823 |
| Furosemide | 118 | $708 |
| Potassium Chloride | 32 | $634 |
| Doxazosin Mesylate | 46 | $631 |
| Metolazone | 14 | $484 |
| Torsemide | 17 | $416 |
| Losartan Potassium | 56 | $352 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 13 | $350 |
| Lisinopril | 83 | $334 |
| Finasteride | 13 | $285 |
| Spironolactone | 27 | $273 |
| Midodrine Hcl | 11 | $247 |
| Tamsulosin Hcl | 19 | $189 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $190 | $42,99715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 208 nephrology providers in Minnesota.
Other nephrology in Duluth
- Prince SinghDuluth$26K
- Elyas SafarDuluth$18K
- Shyam BhupalamDuluth$1K
- Sreedhar DevathiDuluth$1K
- Danijela MataicDuluth$555
- Neera DahlRochester$102K
- Fernando FervenzaRochester$102K
- Kirsten JohansenMinneapolis$101K
- Jeffrey KohenMinneapolis$56K
- James WetmoreMinneapolis$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.